AR064015A1 - Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio - Google Patents

Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio

Info

Publication number
AR064015A1
AR064015A1 ARP070105287A ARP070105287A AR064015A1 AR 064015 A1 AR064015 A1 AR 064015A1 AR P070105287 A ARP070105287 A AR P070105287A AR P070105287 A ARP070105287 A AR P070105287A AR 064015 A1 AR064015 A1 AR 064015A1
Authority
AR
Argentina
Prior art keywords
inhibition
aquaporine
arni
pio
treatment
Prior art date
Application number
ARP070105287A
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of AR064015A1 publication Critical patent/AR064015A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporciona ribointerferencia para la inhibicion de acuaporina 1 (ACP1) en afecciones relacionadas con la presion intraocular, incluyendo la hipertension ocular y el glaucoma tal como el glaucoma de tension normal y el glaucoma de ángulo abierto.
ARP070105287A 2006-11-28 2007-11-29 Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio AR064015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86167106P 2006-11-28 2006-11-28

Publications (1)

Publication Number Publication Date
AR064015A1 true AR064015A1 (es) 2009-03-04

Family

ID=39468676

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105287A AR064015A1 (es) 2006-11-28 2007-11-29 Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio

Country Status (4)

Country Link
US (1) US20080171719A1 (es)
AR (1) AR064015A1 (es)
TW (1) TW200922604A (es)
WO (1) WO2008067373A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092142A2 (en) * 2007-01-26 2008-07-31 Alcon Research, Ltd. Rnai-mediated inhibition of aquaporin 1 for treatment of ocular neovascularization
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
CN109536499B (zh) * 2018-12-12 2022-03-11 广西壮族自治区生殖医院 一种干扰片段及其应用
CN114908090A (zh) * 2021-02-07 2022-08-16 广州瑞风生物科技有限公司 靶向破坏Aqp1 mRNA的sgRNA及其载体与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034009B2 (en) * 1995-10-26 2006-04-25 Sirna Therapeutics, Inc. Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
WO2002044321A2 (en) * 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
PT2284266E (pt) * 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
US7790867B2 (en) * 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
WO2004069181A2 (en) * 2003-02-03 2004-08-19 Pharmacia Corporation Composition for the treatment of intraocular pressure
CA2604333A1 (en) * 2005-04-15 2006-10-19 Cenix Bioscience Gmbh Human marker genes and agents for cardiovascular disorders and artherosclerosis

Also Published As

Publication number Publication date
US20080171719A1 (en) 2008-07-17
TW200922604A (en) 2009-06-01
WO2008067373A3 (en) 2008-12-04
WO2008067373A2 (en) 2008-06-05

Similar Documents

Publication Publication Date Title
UY29348A1 (es) Inhibición de objetivos oculares mediada por arni
CR8498A (es) Derivados de prostaglandinas
AR057252A1 (es) Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
AR064015A1 (es) Inhibicion mediada por arni de acuaporina 1 para tratamiento de afecciones relacionadas con pio
GT200600277A (es) Derivados de prostaglandina
CL2013002467A1 (es) Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.
UY28126A1 (es) Uso de glucocorticoides selectivos para la superficie ocular en el tratamiento de la sequedad ocular
AR062046A1 (es) Soluciones oftalmicas
EA201071413A1 (ru) Способ и композиция для лечения повышения внутриглазного давления и глаукомы
CU24056B1 (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hematológicas
SV2009003098A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
NI200800176A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la depresión
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
RU2017139870A (ru) Новые агонисты npr-b
UY30033A1 (es) Uso de derivados heterociclicos benzo _fusionados de sulfamida para el tratamiento de la obesidad
UY29802A1 (es) Análogos de la feniletilamina y su uso en el tratamiento del glaucoma
BRPI0406879A (pt) Dispositivo de liberação sustentada e método para a liberação ocular de agentes adrenérgicos
AR064016A1 (es) Inhibicion mediada por arni de acuaporina 4 para tratamiento de afecciones relacionadas con pio
AR060222A1 (es) Uso de inhibidores de jun quinasas n- terminales para tratar glaucoma
CL2012002612A1 (es) Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma.
ECSP12012033A (es) Triple combinación para bajar la presión intraocular
AR067786A1 (es) Inhibicion relacionada con arni (arn de interferencia) de senales tnfalfa (factor de necrosis tumoral) para el tratamiento de glaucoma
WO2006007227A3 (en) Abnormal cannabidiols for lowering intraocular pressure
ATE525349T1 (de) Pharmazeutische prostaglandinzusammensetzungen
UY33562A (es) Agonistas de receptores de bradicinina y su utilización para el tratamiento de la hipertensión ocular y el glaucoma

Legal Events

Date Code Title Description
FB Suspension of granting procedure